Stellar Biotechnologies shares jump on vax deal; Morning shots could be better for men;

> Stellar Biotechnologies has licensed-in rights to C. difficile vaccine technology and saw its shares jump by a third. Press release | Article

> A group of institutions in San Antonio is launching the San Antonio Vaccine Development Center. Article

> Nuron Biotech has licensed Vitruvian BioMedical's DNA vaccine against amyloid beta 42 for the treatment of Alzheimer's disease. Press release

> GlaxoSmithKline's ($GSK) malaria vaccine, RTS,S (Mosquirix), is showing efficacy in Rwanda and other African countries. News

> The Vietnamese Ministry of Health is conducting Phase III trials of an H5N1 vaccine in 1,000 healthy volunteers. Item

> Keeping babies warm during jabs is the best pain relief. Report

> Changing the timing of jabs could improve immunity; a study has suggested immunizing men in the morning and women in the afternoon. Article

> HIV researchers get $2.7 million to develop HIV vaccines. Press release

And Finally… Vaccine developer Mymetics has appointed Grant Pickering as president and CEO and Christopher Henney as chair of the board of directors. Press release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.